Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR)-Reference-Cited by-同舟云学术

Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR)

Published:2020-01-27 Issue:8 Volume:22 Page:1378-1389
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Valero J.^ORCID,Peleteiro P.,Henríquez I.,Conde A.,Piquer T.,Lozano A.,Soler C. C.,Muñoz J.,Illescas A.,Jove J.,Flores M. M.,Baquedano J.,Diezhandino P.,de Celis R. P.,Pardo E. H.,Samper P.,Villoslada I.,Eguiguren M.,Millan V.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-019-02274-w.pdf

Reference57 articles.

1. Assiskis VJ, Do KA, We S, et al. Clinical and biomarker correlates of androgen-independent locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004;10:6770–8.

2. Heidenreich A, Bastian P, Bellmunt J, et al. EAU guidelines on prostate cancer Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.

3. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, plattaform randomized controlled trial. Lancet. 2016;387:1163–77.

4. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.

5. Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomized, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153–63.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy;American Journal of Clinical Oncology;2024-08-01

2. Advancements in nanomedicine: Precision delivery strategies for male pelvic malignancies – Spotlight on prostate and colorectal cancer;Experimental and Molecular Pathology;2024-06

3. Novel solid self-emulsifying drug delivery system to enhance oral bioavailability of cabazitaxel;International Journal of Pharmaceutics;2024-04

4. Rethinking the effects of adjuvant beam radiation therapy on overall survival in atypical meningioma patients: age considerations;Frontiers in Neurology;2024-03-15

5. Antitumor activity of alkylphospholipid edelfosine in prostate cancer models and endoplasmic reticulum targeting;Biomedicine & Pharmacotherapy;2023-11